Alzheimer's disease is a progressive degenerative disease of the brain accounting for the majority of dementia seen in the UK  
  
Non\-pharmacological management  
* NICE recommend *offering* 'a range of activities to promote wellbeing that are tailored to the person's preference'
* NICE recommend *offering* group cognitive stimulation therapy for patients with mild and moderate dementia
* other options to *consider* include group reminiscence therapy and cognitive rehabilitation

  
Pharmacological management  
* NICE updated it's dementia guidelines in 2018
* the three acetylcholinesterase inhibitors (donepezil, galantamine and rivastigmine) as options for managing mild to moderate Alzheimer's disease
* memantine (an NMDA receptor antagonist) is in simple terms the 'second\-line' treatment for Alzheimer's, NICE recommend it is used in the following situation reserved for patients with
	+ moderate Alzheimer's who are intolerant of, or have a contraindication to, acetylcholinesterase inhibitors
	+ as an add\-on drug to acetylcholinesterase inhibitors for patients with moderate or severe Alzheimer's
	+ monotherapy in severe Alzheimer's

  
Managing non\-cognitive symptoms  
* NICE does not recommend antidepressants for mild to moderate depression in patients with dementia
* antipsychotics should only be used for patients at risk of harming themselves or others, or when the agitation, hallucinations or delusions are causing them severe distress

  
Donepezil  
* is relatively contraindicated in patients with bradycardia
* adverse effects include insomnia
